Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

Araki, Kazuhiro; Ito, Yoshinori; Fukada, Ippei; Kobayashi, Kokoro; Miyagawa, Yoshimasa; Imamura, Michiko; Kira, Ayako; Takatsuka, Yuichi; Egawa, Chiyomi; Suwa, Hirofumi; Ohno, Shinji; Miyoshi, Yasuo

doi:10.1186/s12885-018-4888-2

BMC Cancer

Article metrics
Last updated: Fri, 26 Apr 2024 3:13:47 Z

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

Access & Citations

2945

Article Accesses
30

Web of Science
28

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com